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Abstract The activation of signal transducer and activa-
tor of transcription 3 (STAT3) has been identiWed as a key
mediator that drives the fundamental components of mela-
noma malignancy, including immune suppression in mela-
noma patients. Increasing evidence also suggests that
regulatory T cells (Tregs) are important in suppressing anti-
tumor immunity and play a dominant role in negating
eYcacious immunotherapy approaches. We hypothesized
that WP1066, a novel inhibitor of STAT3 signaling,
reverses immune suppression through the inhibition of
Tregs and that this contributes to the antitumor activity of
this agent against melanoma brain metastases. We found
that the mean percentage of peripheral blood mononuclear
cells expressing phosphorylated STAT3 (p-STAT3) was
signiWcantly elevated in samples from patients with mela-
noma brain metastases compared to healthy donors,
16.13 § 2.48% versus 4.17 § 1.79%. The p-STAT3 inhibi-
tor WP1066 enhanced CD3+ (which contained Tregs) but
not CD8+ T cell cytotoxicity against human A375 mela-
noma cells, indicating that this p-STAT3 blockade agent
did not directly activate CD8+ T cells. Furthermore, the
p-STAT3 inhibitor did not enhance the cytotoxicity of
CD3+CD25¡ T cells (from which Tregs were excluded),
indicating that the enhanced cytotoxicity of WP1066 is sec-
ondary to its inhibition of Tregs. This was conWrmed by
demonstrating that WP1066 inhibited FoxP3+ Treg induc-
tion in a dose-dependent manner. Moreover, CD3+ T cells
exhibited markedly enhanced levels of phosphorylated
ZAP-70, a critical proximal signal in T cell activation, after
exposure to WP1066. Similar eVects were not observed in
Treg-depleted CD3+CD25¡ T cell populations, conWrming
that the T cell activation by WP compounds is secondary to
their inhibition of the Tregs. These results suggest that
WP1066 enhances T cell cytotoxicity against melanoma
through inhibition of Tregs.
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Introduction
Upon metastasis to the central nervous system (CNS), mel-
anoma is associated with a median survival time of less
than 1 year. The development of new eVective therapies for
metastatic melanoma to the CNS is a major unmet clinical
need. Signal transducer and activator of transcription 3
(STAT3) is a clinically signiWcant latent transcription fac-
tor whose phosphorylation results in its activation, its
nuclear translocation, and the upregulation of various onco-
genic gene products [16]. Phosphorylated STAT3 (p-
STAT3) serves as an intersection point for many upstream
pathways including interleukin (IL)-6, which is expressed
in the CNS under a wide variety of conditions [9, 19, 32],
that activate Jak2 then STAT3 by phosphorylation of the
tyrosine residue in the transactivation domain of STAT3
[20]. Aberrant or overactive STAT3 is correlated with
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1024 Cancer Immunol Immunother (2009) 58:1023–1032tumor cell proliferation, abnormal cell cycling, vascular
endothelial growth factor overproduction and angiogenesis,
impaired apoptotic mechanisms [16], and, of critical impor-
tance, immune escape. This last process, by which tumor
cells are able to avoid detection and destruction by a
patient’s immune system, promotes tumor aggression,
malignancy, and metastasis [12, 23, 30, 33].
STAT3-mediated immune escape is particularly relevant
in cases of metastatic melanoma not only due to the strong
correlation between p-STAT3 expression and melanoma
malignancy, but also because of the potential susceptibility
of melanoma to immunotherapy [26]. In human melanoma
patients, constitutive STAT3 was observed in the majority
of tested melanoma cell lines and primary tumors, but not
in normal skin specimens matched from the same patients
[22] or from compound or dysplastic nevus tissues [37].
A study by Xie et al. [35] conWrmed the importance of
STAT3 in melanoma metastasis by showing that only
highly metastatic melanoma cell lines, not poorly meta-
static ones, have elevated levels of p-STAT3. In addition,
blockade of p-STAT3 by the expression of dominant-nega-
tive STAT3 signiWcantly suppresses matrix metalloprotein-
ase 2 (MMP-2) expression and the invasiveness of
melanoma cells, inhibits tumor growth, and prevents metas-
tasis in nude mouse model systems [35]. A subsequent
study of brain metastasis in humans with melanoma have
demonstrated high levels of activated STAT3 more com-
monly in brain metastasis specimens than in parenchymal
tumors, indicating that p-STAT3 is a key enhancer of
malignancy in melanoma [34].
p-STAT3 also becomes upregulated within the immune
cells upon association with a variety of cancers [17]. Mice
with ablation of Stat3 in their hematopoietic cells have
marked antitumor clearance by the immune system and a
reduction in the number of tumor-inWltrating regulatory
T cells (Tregs) [17]. Further, STAT3 is required for both
transforming growth factor (TGF)- and IL-10 production
by CD4+ T cells [14], factors necessary for the generation
of tumor-associated Tregs. In addition, IL-2 has been
shown to regulate FoxP3 expression in human
CD4+CD25+ Tregs by STAT3 binding of the Wrst intron
of the FoxP3 gene [38]. Thus, STAT3 is a key signaling
molecule for the generation of the immune suppressive
Treg component in patients with cancer. Furthermore,
CD3+CD25+FoxP3+ Tregs are present within CNS mela-
noma metastases and peritumoral tissue [15].
We previously showed that WP1066, a novel small
molecule inhibitor of p-STAT3, induces phosphorylated
ZAP-70 (p-ZAP-70; Tyr319), a critical signal in T cell acti-
vation, and increases T cell proliferation [13]. We hypothe-
sized that STAT3 blockade agents could enhance T cells’
cytotoxic activity against melanoma through the inhibition
of Tregs and that this would contribute to the antitumor
activity of this agent against melanoma brain metastases.
To investigate how p-STAT3 inhibitors act upon T cells
from immune suppressed melanoma patients, T cells from
melanoma brain metastasis patients were isolated and ana-
lyzed for their cytotoxicity against melanoma cells with and
without the presence of Tregs. Delineating the mechanism
of activity of STAT3 inhibitors is crucial since these com-
pounds could be utilized as immune therapeutics, especially
for cancers within the CNS.
Materials and methods
Cell line
The human melanoma cell line A375 was provided by Dr.
Elizabeth Grimm (The University of Texas M. D. Anderson
Cancer Center, Houston, TX) and was maintained in RPMI
1640 medium supplemented with 10% fetal bovine serum
at 37°C in a humidiWed atmosphere of 5% CO2 and 95% air
and was free of mycoplasma contamination.
STAT3 inhibitor
WP1066 [11, 24], which blocks p-STAT3 [21, 25], was
synthesized and supplied by Dr. Waldemar Priebe (M. D.
Anderson). WP1066 was dissolved in dimethylsulfoxide
(DMSO, Sigma-Aldrich, St Louis, MO) as stock solution
and serially diluted to the desired concentration with RPMI
1640 medium. The Wnal concentration of DMSO in cell cul-
ture systems was <0.05%.
Human subjects
Patients with brain metastases from melanoma who were to
undergo surgical resection were recruited for the study.
Peripheral blood was drawn from the patients intraopera-
tively. Peripheral blood was also drawn from healthy vol-
unteer donors. The melanoma metastasis, after resection
and veriWcation of pathology by a neuropathologist, was
transported on ice from the operating room and was frozen
immediately upon arriving at the laboratory for protein iso-
lation and Western blot analysis. This study was approved
by the institutional review board of The University of
Texas M. D. Anderson Cancer Center (LAB03-0687), and
written informed consent was obtained.
Isolation of peripheral blood mononuclear cells 
and staining for p-STAT3 expression
Blood samples were mixed with an equal volume of sterile
phosphate-buVered saline (PBS) and subjected to density
gradient centrifugation using Ficoll-Paque (Amersham123
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clear cells (PBMCs) were isolated and washed twice with
PBS. For Wxation, 5 £ 106 cells were resuspended in 0.5 ml
of PBS, 37°C pre-warmed paraformaldehyde was added to
achieve a Wnal concentration of 1%, and the solution was
incubated for 10 min at 37°C and then chilled on ice for
1 min. For permeabilization, the paraformaldehyde was
removed by pelleting the cells at 1,500 rpm for 5 min and
resuspending them in 90% methanol, and then the cells
were incubated for 30 min on ice and pelleted at 1,500 rpm
for 5 min; 1 £ 106 cells were seeded in duplicate into wells
of 96 v-bottom well plates, centrifuged for 5 min at
1,500 rpm, and washed once with Xuorescence-activated
cell sorter (FACS) buVer (PBS with 0.5% bovine serum
albumin [BSA]) for 5 min at 1,500 rpm. The cells were
resuspended in 45 l of FACS buVer/well and 5 l of
mouse phycoerythrin (PE)-labeled anti-human p-STAT3
(Y705) antibody (BD Biosciences, San Jose, CA). Matched
control wells included 5 l of PE-labeled IgG2a- isotype
control (eBioscience, San Diego, CA). The cells were incu-
bated for 60 min at room temperature, washed with 200 l
of FACS buVer/well, centrifuged for 5 min at 1,500 rpm,
resuspended in 250 l of FACS buVer/well, and transferred
to FACS tubes for Xow analysis with FACSCalibur (BD
Biosciences).
T cell enrichment
PBMCs from healthy donors were pelleted and resus-
pended in FACS buVer and 2 mM EDTA to achieve a Wnal
cell concentration of 1 £ 107 cells/ml. The Pan T cell isola-
tion kit II protocol (Miltenyi Biotec, Auburn, CA) was uti-
lized as speciWed in the kit instructions. BrieXy, 1 l of T
cell biotin-antibody cocktail (Miltenyi Biotec) was added to
the PBMCs suspended in FACS buVer, and the solution
was gently vortexed and incubated at 4°C for 10 min.
Thereafter, 1 l of anti-biotin microbeads (Miltenyi Biotec)
per 106 cells was added. The cells were vortexed, incubated
at 4°C for 15 min, and then washed and resuspended in
FACS buVer to achieve a Wnal concentration of
2 £ 108 cells/ml. The T cells were fractionated using nega-
tive-selection LS columns (Miltenyi Biotec) loaded with
2 £ 108 PBMCs per column. The T cell fractions were
pooled and counted, spun down, and resuspended in RPMI
1640 medium to be used for puriWcation of T cell subpopu-
lations and cytotoxicity assays.
PuriWcation of T cell subpopulations
T cells suspended in RPMI 1640 medium were labeled with
75 l each of PE-conjugated anti-CD3, allophycocyanin
(APC)-conjugated anti-CD8, and Xuorescein isothiocyanate
(FITC)-conjugated anti-CD25 antibodies (Miltenyi Biotec)
per 1 £ 108 cells. After incubation at 4°C for 40 min, the
labeled cells were washed twice with FACS buVer and
resuspended in FACS buVer with 1 mM EDTA to achieve a
Wnal concentration of 4 £ 107 cells/ml. The cells were then
passed through a 40-m cell strainer. Single-color samples
were made for calibration, and the CD3+, CD3+CD25¡,
and CD8+ T cells were sorted on a FACSAria Cell Sorter
(BD Biosciences). Since the intracellular staining process
for FoxP3 in Tregs would permeabilize the membrane and
aVect Treg viability and subsequent response to the STAT3
blockade agents, we elected to obtain Treg-depleted CD3 T
cells (CD3+CD25¡) by sorting Tregs (CD3+CD25+) out
from the CD3+ population. Functional Tregs have the sur-
face phenotype CD3+CD25+; thus, the presence of the
Tregs should be minimized in this post-sorted cell popula-
tion.
T cell cytotoxicity assay against melanoma cells
A375 cells in RPMI 1640 medium were cultured for 3 days,
trypsinized, pelleted, and resuspended in FACS buVer at
room temperature to achieve a concentration of 106 cells/
ml. Carboxy–Xuorescein diacetate succinimidyl ester
(CFSE) stock solution (CellTrace CFSE Cell Proliferation
Kit; Invitrogen, Eugene, OR) was added to achieve a Wnal
concentration of 4 M, the mixture was incubated at 37°C
for 10 min, and then the staining reaction was quenched by
the addition of Wve volumes of ice-cold PBS for 5 min. The
A375 cells were washed 3 times in RPMI 1640 medium
and plated for the cytotoxicity assay. The ratio of CD3+ or
CD3+CD25¡ T eVector cells to A375 target cells was 3.5:1
when using cells from healthy donors and 10:1 when using
cells from melanoma brain metastasis patients because of
immune incompetence in cancer patients. Treatment groups
consisted of A375 target cells alone; A375 cells in the
presence of 2 M WP1066; A375 cells with CD3+ or
CD3+CD25¡ T cells; A375 cells with CD3+ or
CD3+CD25¡ T cells in the presence of 2 M WP1066. In
another group of experiments, the CD8+ T eVector cell to
A375 target cell ratio was 5:1. Treatment groups consisted
of A375 target cells alone; A375 cells in the presence of
2 M WP1066; CD8+ T cells with A375 cells; and CD8+ T
cells with A375 cells in the presence of 2 M WP1066.
After 48 h of incubation, the CFSE-labeled A375 mela-
noma cells were removed from the plates with trypsin and
analyzed by FACS. The A375 cells were stained with pro-
pidium iodide (PI; BD Biosciences) to distinguish viable
cells from nonviable cells. A375 cells that were stained
with CFSE and PI were considered nonviable. Flow cytom-
etry acquisition of the A375 target cells was done with a
FACS Calibur Xow cytometer (BD Biosciences), and data
analysis was done using FlowJo software (TreeStar,
Ashland, OR).123
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Resected melanoma brain metastases were used for protein
isolation and immunoblotting analysis as described below.
PBMCs, CD3+ T cells, and CD3+CD25¡ T cells from
healthy donors and melanoma brain metastasis patients
were puriWed as described above. PBMCs, CD3+ T cells,
or CD3+CD25¡ T cells were seeded at a density of
1 £ 106 cells/well in 6-well culture plates and incubated at
37°C, in an atmosphere containing 5% CO2, with the RPMI
1640 medium in absence or presence of 5 M WP1066.
After 2 h, the PBMCs were further cultured in absence or
presence of 10 ng/ml of IL-6 for 15 min. Afterwards, all
above cells were pelleted and rinsed with ice-cold PBS
at 1,500 rpm for 5 min. The cells were lysed for 30 min in
ice-cold lysis buVer [50 mM Tris–HCl (pH 8.0), 150 mM
NaCl, 1 mM EDTA] containing 1% Triton-X-100 and
phosphatase and protease inhibitors (Sigma-Aldrich). The
lysates were centrifuged at 14,000 rpm for 10 min at 4°C.
The supernatants were collected and quantiWed for protein
content. Equal amounts of proteins (20 g) were electro-
phoretically fractionated in 8% sodium dodecyl sulfate
(SDS)-polyacrylamide gels, transferred to nitrocellulose
membranes, and subjected to immunoblot analysis with
speciWc antibodies against p-STAT3 (Tyr705), STAT3,
p-ZAP-70 (Tyr319), ZAP-70 (Cell Signaling Technology,
Inc., Danvers, MA), and -actin (Sigma-Aldrich). Autora-
diography of the membranes was performed using Amer-
sham ECL Western blotting detection reagents (Amersham
Biosciences). The densities of the protein bands compared
to the -actin protein control were measured with Image J
program provided by the NIH (http://rsb.info.nih.gov/ij/
index.html).
Induction Treg assays
Because of limitations on blood sample volumes that can be
obtained from patients undergoing surgery as well as the
low percentage of Tregs in PBMCs, it was impractical to
isolate suYcient Tregs for analysis of their response to
STAT3 blockade in melanoma brain metastasis patients.
To assess whether WP1066 is capable of inhibiting Tregs,
especially since this immune population is a key factor
mediating immune suppression in cancer patients [6],
including melanoma patients, we used an in vitro Treg
induction system in which FoxP3 expression was induced
in naïve CD4+ T cells isolated from mice whose spleens
can provide a far more enriched source of naïve CD4+ cells
than human blood samples, which must be limited to vol-
umes insuYcient for CD4+CD25¡CD62Lhi extraction.
FoxP3+ Treg generation was directly measured by intracel-
lular staining for FoxP3 protein expression. In this system,
naïve CD4+ T cells underwent robust FoxP3+ Treg diVer-
entiation when they were activated by polyclonal stimula-
tion in the presence of exogenous TGF-.
Single cell suspensions were prepared from pooled
lymph nodes and spleens of C57BL/6 J mice (MD Ander-
son Cancer Center, Houston, TX). The CD4+ cells were
enriched using CD4 MACS beads (Miltenyi Biotec) and
were stained with PerCP (peridinin–chlorophyll–protein
complex)-labeled anti-CD4 (L3T4), FITC-labeled anti-
CD62L (MEL-14), and APC-labeled anti-CD25 (PC61)
antibodies (Miltenyi Biotec). The cells were further
sorted on a FACSAria cell sorter (BD Biosciences) to
obtain pure populations of naïve CD4+CD25¡CD62Lhi
T cells. Naïve CD4+CD25¡CD62Lhi cells were then
incubated on anti-CD3-coated plastic plates (2 g/ml) in
complete RPMI 1640 medium with soluble anti-CD28
(2 g/ml) antibody and rTGF-1 (1 ng/ml) to induce
FoxP3+ Tregs. The cultures were supplemented with
WP1066 at concentrations of 0, 1, 2, and 4 M for 48 h.
PerCP-conjugated anti-CD4 (L3T4) and APC-conjugated
anti-CD25 (PC61) monoclonal antibodies were used for
cell surface staining. To detect FoxP3 protein expression,
the surface-stained cells were further subjected to
intracellular staining with PE-conjugated monoclonal
antibodies to FoxP3 (clone FJK-16s; eBioscience) using
the staining buVers and conditions speciWed by the
manufacturer.
Statistical analysis
Data are presented as mean § standard errors (SEs) of three
repeated experiments. Student’s t test was performed. A P
value below 0.05 was considered statistically signiWcant.
Results
Expression of p-STAT3 is enhanced in PBMCs 
from melanoma brain metastasis patients 
and can be blocked with WP1066
Melanoma brain metastases commonly express p-STAT3
(Fig. 1a). Since p-STAT3 expressing tumors have been
shown to induce p-STAT3 expression in tumor associated
immune cells and since these immune cells can regain
access back to the peripheral circulation, we next deter-
mined if the PBMCs had increased expression of p-STAT3.
PBMCs were isolated from both healthy donors (n = 14)
and melanoma brain metastasis patients (n = 10) and ana-
lyzed via FACS for p-STAT3 levels. The percentage of p-
STAT3-expressing PBMCs from melanoma patients
(16.13 § 2.48%) was signiWcantly elevated compared to
the mean from healthy donors (4.17 § 1.79%, P < 0.05)
(Fig. 1b). Of note, the expression of p-STAT3 is lost within123
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if the p-STAT3 inhibitor WP1066 could down modulate
both constitutive and induced expression of p-STAT3
in PBMCs. In order to recapitulate the CNS biology of
PBMCs within the CNS, IL-6 was added. By scanning den-
sitometry, in comparison to respective non-treated controls,
WP1066 signiWcantly reduced the levels of both constitu-
tive and IL-6-induced p-STAT3 by 52.4 and 61.5%, respec-
tively. Regardless of the systemic or CNS microenvironment,
WP1066 was capable of down modulating p-STAT3 sig-
naling (Fig. 1c).
STAT3 inhibitor WP1066 enhances CD3+ T cell 
cytotoxicity against melanoma
The ratio of CD3+ or CD3+CD25¡T eVector cells to A375
target cells was 3.5:1 when using cells from healthy donors
and 10:1 when using cells from melanoma brain metastasis
patients because of immune incompetence in cancer
patients. WP1066 markedly enhanced the cytotoxicity of
CD3+ T cells from healthy donors, 26.3 § 3.1% versus
13.4 § 0.6% (P < 0.05) (Fig. 2a), and melanoma brain
metastasis patients, 24.1 § 2.1% versus 15.2 § 1.0%
(P < 0.05) (Fig. 2b), against human melanoma A375 cells,
indicating that this compound can enhance T cell cytotoxic-
ity. Minimal apoptosis of A375 cells, 2.7 § 0.2%, was seen
when 2 M of WP1066 (below the IC50) was used alone
(Fig. 2).
WP1066 does not primarily activate CD8+ T cells
To determine whether the STAT3 blockade agent WP1066
directly activates CD8+ T cells, A375 cytotoxicity assays
were performed in various combinations with CD8+ T cells
obtained from healthy donors as well as from melanoma
brain metastasis patients. WP1066 did not enhance the
cytotoxicity against human melanoma A375 cells by CD8+
cells obtained from either healthy donors or melanoma
brain metastasis patients (Fig. 3).
Depletion of Tregs abolishes WP1066-enhanced 
CD3+ T cell cytotoxicity against melanoma
Since there was no direct enhancement of CD8+ T cell
cytotoxicity by WP1066, we suspected that the mecha-
nism by which STAT3 blockade enhanced the cytotoxic-
ity of CD3+ populations could involve the inhibition of
immunosuppressive agents, such as Tregs, within that
population. The CD3+CD25¡ population (Treg depleted)
was assayed for cytotoxicity against human melanoma
A375 cells with and without the WP1066 (Fig. 4). As
before, 2 M of WP1066 by itself did not increase apopto-
sis in human melanoma A375 target cells. Furthermore,
WP1066 did not enhance the cytotoxicity of
CD3+CD25¡ T cells from healthy donors, 17.1 § 0.5%
versus 18.7 § 0.2% (P > 0.05) (Fig. 4a), or melanoma
brain metastasis patients, 12.1 § 0.9% versus 13.8 §
0.6% (P > 0.05) (Fig. 4b), indicating that the enhanced
cytotoxicity of WP1066 observed with the CD3+ T cells
(Fig. 2) likely derives from the ability of WP1066 to
inhibit Tregs.
Fig. 1 Expression of p-STAT3 is enhanced in PBMCs from mela-
noma brain metastasis patients and is blocked with WP1066. a Mela-
noma brain metastases express p-STAT3. The resected melanoma
metastases were lysed, electrophoretically fractionated in 8% SDS-
polyacrylamide gels, transferred to nitrocellulose membranes, and
immunoblotted with antibodies to p-STAT3 (Tyr705), STAT3, or
-actin. b Expression of p-STAT3 is enhanced in PBMCs from
melanoma brain metastasis patients. PBMCs were isolated from blood
samples obtained from healthy donors (n = 14) and melanoma brain
metastasis patients (n = 10), Wxed in paraformaldehyde, permeabili-
zed, stained with mouse PE-labeled anti-human p-STAT3 (Y705) anti-
body, and analyzed by FACS. The percentage of p-STAT3-positive
PBMCs diVered signiWcantly (P < 0.05) between healthy donors and
melanoma brain metastasis patients. c WP1066 inhibits p-STAT3 in
PBMCs from melanoma brain metastasis patients. The PBMCs were
incubated with either the RPMI 1640 medium alone or supplemented
with WP1066 in the presence or absence of 10 ng/ml of IL-6. Subse-
quently, cells were lysed, electrophoretically fractionated in 8% SDS-
polyacrylamide gels, transferred to nitrocellulose membranes, and
immunoblotted with antibodies to p-STAT3 (Tyr705), STAT3, or
-actin
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phosphorylation of ZAP-70 in CD3+ T cells
Since the phosphorylation of ZAP-70 is immediately down-
stream of the T cell receptor but proximal to other markers
of T cell activation including STAT3, we examined the
eVects of WP1066 on p-ZAP-70 in CD3+ T cells with and
without the presence of Tregs from healthy donors as well
as melanoma brain metastasis patients. After exposure to
WP1066, the CD3+ T cells (that would contain Tregs) from
the healthy donors and the melanoma brain metastasis
patients, demonstrated a 78.8 and 56% enhancement of
p-ZAP-70, respectively (Fig. 5). However, WP1066 did not
enhance p-ZAP-70 in the CD3+CD25¡T cells (that would
lack Tregs), indicating that WP1066 enhancement of
p-ZAP-70 is secondary to the inhibition of Tregs (Fig. 5).
Fig. 2 WP1066 enhances the cytotoxicity of CD3+ T cells against hu-
man melanoma A375 cells. A375 cells were labeled with CFSE and
exposed to multiple experimental conditions in the presence of CD3+
cells from healthy donors (Fig. 2a, eVector:target cell ratio = 3.5:1) and
melanoma brain metastasis patients (Fig. 2b, eVector:target cell
ratio = 10:1). A375 cells were grown in triplicate cultures in RPMI
1640 medium alone or supplemented with 2 M of WP1066, CD3+ T
cells, or CD3+ T cells plus 2 M of WP1066. Flow cytometry was used
to determine the percentage of PI-positive cells for each experimental
condition. *P < 0.05 in comparison with the CD3+ PBMC group.
These experiments were reproduced four times with similar results
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Fig. 3 The eVect of WP1066 on the cytotoxicity of CD8+ T cells
against human melanoma A375 cells. A375 cells labeled with CFSE
were exposed to multiple experimental conditions in the presence or
absence of CD8+ T cells from healthy donors (eVector:target cell
ratio = 5:1). Cells were grown in triplicate cultures in RPMI 1640
medium alone or supplemented with 2 M of WP1066, CD8+ T cells,
or CD8+ T cells plus 2 M of WP1066. Flow cytometry was used to
determine the percentage of PI-positive cells for each experimental
condition. There were no statistically signiWcant diVerences between
the CD8+ T cell group and CD8+ T cell plus WP1066 group. These
experiments were reproduced four times with similar results
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cytotoxicity against human melanoma A375 cells. The experiment in
Fig. 2 was repeated with CD3+CD25¡T cells after depleting Tregs
(CD3+CD25+) with a FACSAria cell sorter. A375 cells were labeled
with CFSE and exposed to multiple experimental conditions in the
presence or absence of CD3+CD25¡ cells from healthy donors
(Fig. 3a, eVector:target cell ratio = 3.5:1) and melanoma brain metas-
tasis patients (Fig. 3a, eVector:target cell ratio = 10:1). Cells were
grown in triplicate cultures in RPMI 1640 medium alone or supple-
mented with 2 M of WP1066, CD3+CD25¡ T cells, or CD3+CD25¡
T cells plus 2 M of WP1066. Flow cytometry was used to determine
the percentage of PI-positive cells for each experimental condition.
*P < 0.05 in comparison with the CD3+CD25¡ PBMC group. These
experiments were reproduced four times with similar results
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Fig. 5 Depletion of Tregs abolishes WP1066-enhanced phosphoryla-
tion of ZAP-70 (p-ZAP-70) in CD3+ T cells. CD3+ and CD3+CD25¡
T cells were isolated from the PBMCs of healthy donors, and mela-
noma brain metastasis patients. The cells were incubated with either
the RPMI 1640 medium alone or supplemented with WP1066. Subse-
quently, cells were lysed, electrophoretically fractionated in 8% SDS-
polyacrylamide gels, transferred to nitrocellulose membranes, and
immunoblotted with antibodies to p-ZAP-70 (Tyr319), ZAP-70, phos-
phorylated AKT (p-AKT: Ser473), AKT, or -actin. These experi-
ments were reproduced four times with similar results
50 0 5
Healthy Donor  
0 5 0 5
Melanoma Brain Metastasis Patient
µM WP1066
p-ZAP-70 (Tyr319)
ZAP-70
β-Actin
CD3+CD25-CD3+ CD3+CD25-CD3+
Fig. 6 WP1066 inhibits inducible Tregs. CD4+ cells enriched from
pooled lymph nodes and spleens of C57BL/6 J mice were stained with
PerCP-labeled anti-CD4 (L3T4), FITC-labeled anti-CD62L (MEL-
14), and APC-labeled anti-CD25 (PC61) antibodies. A FACSAria cell
sorter was used to obtain naïve CD4+CD25¡ CD62Lhi T cells, which
were stimulated with anti-CD3 antibody (2 g/ml), anti-CD28 anti-
body (2 g/ml), and rTGF-1 (1 ng/ml) to induce FoxP3+ Tregs. The
cultures were supplemented with WP1066 at the concentrations shown
for 48 h, then stained with PerCP-conjugated anti-CD4 and APC-con-
jugated anti-CD25 antibodies, permeabilized, and stained with PE-
conjugated mAbs to FoxP3. Tregs (high CD4, high FoxP3) are plotted
as the percentage of overall T cells for each experimental condition
1µM
CD4
Fo
xP
3
100 101 102 10 3 10 4
10 0
10 1
10 2
10 3
10 4
2µM
CD4
Fo
xP
3
100 101 102 10 3 10 4
10 0
10 1
10 2
10 3
10 4
4µM
CD4
Fo
xP
3
100 101 102 10 3 10 4
10 0
10 1
10 2
10 3
10 4
0 8.93
91.10
0 4.74
95.30
0 2.18
97.80
Baseline
CD4
Fo
xP
3
100 101 102 10 3 10 4
10 0
10 1
10 2
10 3
10 4
0 16.1
83.90123
1030 Cancer Immunol Immunother (2009) 58:1023–1032WP1066 markedly inhibits inducible Tregs
To determine the eVects of WP1066 on the de novo synthe-
sis of Tregs, we tested WP1066 in an in vitro Treg induc-
tion assay. WP1066 inhibited FoxP3+ Treg induction in a
dose-dependent manner, with 70.6% of inhibition at
2.0 M concentration (Fig. 6), which is achievable in vivo
[13]. Thus, inhibition of p-STAT3 can diminish the induc-
tion of Tregs, which may contribute to the antitumor
responses observed with the use of STAT3 blockade agents
in vivo.
Discussion
ClariWcation of the mechanisms underlying p-STAT3-med-
iated immune suppression will assist in the development of
adjuvant immunotherapies for metastatic melanoma but is
complicated by the fact that p-STAT3 interacts with the
immune system in multiple ways. Mechanisms of immune
evasion mediated by p-STAT3 include down regulation of
the functional activity of antigen-presenting cells such as
dendritic cells, including decreased expression of MHC
class I molecules [17]; inhibition of apoptotic signal recep-
tors; down modulation of co-stimulation; production of
immunosuppressive cytokines [1, 29]; induction of TGF-,
and IL-10 [5, 36]; and an increase of Tregs, which possess
immunosuppressive activity towards antigens from the self,
infectious agents, and tumors [4, 16, 30]. Tregs are abun-
dantly present within melanoma metastasis to the CNS
[15], and this likely contributes to the immunosuppression
and tumor immune evasion that counteract immunological
clearance of the tumor. Our data demonstrate that the p-
STAT3 inhibitor WP1066 inhibits Tregs and enhances the
cytotoxicity of T cells from melanoma brain metastasis
patients against melanoma and that the antitumor activity of
WP1066 derives from its ability to inhibit Tregs.
We previously showed [13] that p-STAT3 blockade
agents such as WP1066 can induce a cytotoxic T cell
response and the phosphorylation of ZAP-70, a proximal
signal directly associated with the activation of the T cell
receptor/CD3 complex. Because Western blot analysis of
key T cell receptor signaling pathways (MEKK/JNK, Raf/
ERK, and NIK/NFKB) did not identify a mechanism by
which the STAT3 blockade directly activated ZAP-70, we
looked for an indirect means of activation. We suspected
that because WP1066 can inhibit Tregs, activation of eVec-
tor T cells may not necessarily result from direct interaction
of STAT3 inhibitors and eVector T cells but rather from
inhibition of the immune inhibitory break (i.e., Tregs). In
this report, we demonstrate that the increase in cytotoxicity
against melanoma cells seen with the p-STAT3 inhibitors is
attributable to the inhibition of Tregs rather than a direct
eVect on the cytotoxicity of T cells. Ideally, one would
investigate the eVects of STAT3 inhibition on human Treg
activity, but this approach is problematic for several rea-
sons. Given the low percentage of Tregs in human PBMCs,
it is not possible to collect the volume of blood needed,
especially during surgery, to isolate suYcient Tregs for
both Western blot analysis and cytotoxicity assays under a
multitude of experimental conditions from the same donor.
Furthermore, cancer patients in general can have an overall
decrease in the CD4 compartment [6]. Finally, because the
consensus marker of Tregs, FoxP3, is intracellular that
would require permeabilization for staining that would alter
functional activity, we had to approach our analysis of
STAT3 inhibitor interactions with Tregs using an indirect
approach: looking at the eVects of Treg depletion on whole
T cell preparations. Western blotting experiments in which
we depleted the CD25+ Treg-inclusive population indi-
cated that the mechanism of T cell activation is secondary
to inhibition of the Tregs. This is further supported by the
inhibition of Tregs by STAT3 blockade in an in vitro induc-
tion assay. These Wndings are also consistent with the Wnd-
ings of others who have shown that Stat3 ablation in
hematopoietic cells using the Mx1–Cre–loxP system is
accompanied by a reduction in the number of tumor-inWl-
trating Tregs [17] and that IL-2 regulates FoxP3 expression
in human CD4+CD25+ Tregs by STAT3 binding of the
Wrst intron of the FoxP3 gene [38]. Thus, the STAT3 block-
ade agents diVer from other Treg modulatory agents like
anti-CD25, which binds to the surface of Tregs and disrupts
functional activity [8], and anti-CTLA4, which confers
resistance to Treg-mediated immunosuppression but not
through a direct eVect on Tregs [7].
Our data provide a rationale to consider p-STAT3 target-
ing in the future in combination with other immunothera-
pies such as IFN-, IL-2, granulocyte-macrophage colony-
stimulating factor, monoclonal antibodies against tumor
antigens, and anti-cancer vaccines [10, 26]. Additionally,
because we have shown that STAT3 blockade has negligi-
ble inhibitory eVects on eVector T cell cytotoxicity against
metastatic CNS melanoma, the unintended loss of CD8+
activity, which could potentially compromise immunologi-
cal tumor clearance, can be minimized. IL-2, which induces
favorable cytotoxic T cell responses, is approved by the US
Food and Drug Administration to treat stage IV melanoma
but has only a 15% objective response rate [2, 3, 28]. One
factor underlying this poor response rate could be that a
potent side eVect of IL-2 therapy is the expansion of Tregs
[38]. The synergistic activity of IL-2 and STAT3 blockade
agents may overcome this limitation of IL-2 and yield a
higher response rate, preserving the expansion of CD8+
cells while inhibiting the induction of Tregs. This is just
one potential strategy of many that would rely upon inhibit-
ing the immunosuppressive eVects of Tregs via inhibition123
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noma [15], the inhibitory eVect of WP1066 on Tregs has
clinical implications, especially considering that immuno-
therapeutic approaches for melanoma have so far been dis-
appointing [27]. Because of their ability to cross the blood-
brain barrier and establish physiologically relevant concen-
trations in the tumor microenvironment [13], the STAT3
blockade agents have great potential for the treatment of
melanoma metastases to the CNS.
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